This suggests high potential for failure of preclinical endocannabinoid studies that aim to evaluate the roles of trpv1 in hyperalgesia, body temperature control, diabetes, hormone secretion, epilepsy and hearing (Aghazadeh Tabrizi et al., 2017), as well as trpv2 in cancer and cardiovascular dysfunction (Gorbunov et al., 2019; Khan et al., 2019; Mangal et al., 2021; Muller et al., 2019). This evidence concerns the gene TRPV1 and epilepsy.